Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
Irene Capelli, Lorenzo Gasperoni, Marco Ruggeri, et al.
Journal of Nephrology (2019) Vol. 33, Iss. 1, pp. 37-48
Closed Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Primary Aldosteronism
Gian Paolo Rossi
Journal of the American College of Cardiology (2019) Vol. 74, Iss. 22, pp. 2799-2811
Closed Access | Times Cited: 125
The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism
Gian Paolo Rossi, Valeria Bisogni, Alessandra Bacca, et al.
International Journal of Cardiology Hypertension (2020) Vol. 5, pp. 100029-100029
Open Access | Times Cited: 106
Pathogenesis and treatment of primary aldosteronism
Maria‐Christina Zennaro, Sheerazed Boulkroun, Fábio L. Fernandes‐Rosa
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 578-589
Open Access | Times Cited: 95
Hypertension in chronic kidney disease: What lies behind the scene
Omar Z. Ameer
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Bioinspired optical and electrical dual-responsive heart-on-a-chip for hormone testing
Lingyu Sun, Yu Wang, Feika Bian, et al.
Science Bulletin (2023) Vol. 68, Iss. 9, pp. 938-945
Closed Access | Times Cited: 34
Finerenone: First Approval
James E. Frampton
Drugs (2021) Vol. 81, Iss. 15, pp. 1787-1794
Closed Access | Times Cited: 51
Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists
Amin Abedini, Andrea Sánchez‐Navarro, Junnan Wu, et al.
Journal of Clinical Investigation (2023) Vol. 134, Iss. 1
Open Access | Times Cited: 17
Clinical Management of Primary Aldosteronism: An Update
Gian Paolo Rossi, Federico Bernardo Rossi, Chiara Guarnieri, et al.
Hypertension (2024) Vol. 81, Iss. 9, pp. 1845-1856
Closed Access | Times Cited: 8
Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism—the EMIRA Study
Gian Paolo Rossi, Giulio Ceolotto, Giacomo Rossitto, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 6, pp. 2060-2067
Open Access | Times Cited: 43
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Jonatan Barrera‐Chimal, Peter Kolkhof, Ixchel Lima‐Posada, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 11, pp. 1141-1157
Open Access | Times Cited: 38
Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension
Utkarsh Ojha, S. Ruddaraju, N N Sabapathy, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 271-285
Open Access | Times Cited: 29
DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases
Yoshimichi Takeda, Masashi Demura, Takashi Yoneda, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4587-4587
Open Access | Times Cited: 28
Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis
Gregorio Romero‐González, Arantxa González, Begoña López, et al.
Nephrology Dialysis Transplantation (2020) Vol. 37, Iss. 5, pp. 817-824
Closed Access | Times Cited: 28
The mineralocorticoid receptor in chronic kidney disease
Jonatan Barrera‐Chimal, Frédéric Jaisser, Hans‐Joachim Anders
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3152-3164
Open Access | Times Cited: 27
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Sebastiaan C. Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 3, pp. 451-462
Open Access | Times Cited: 24
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
Richard Hobbs, Richard J. McManus, Clare Taylor, et al.
Health Technology Assessment (2025), pp. 1-130
Open Access
Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
Jiao Wang, Meijuan Zheng, Yuchun Yang, et al.
ESC Heart Failure (2025)
Open Access
Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence
Elodie Bousquet, Min Zhao, Alejandra Daruich, et al.
Experimental Eye Research (2019) Vol. 187, pp. 107754-107754
Open Access | Times Cited: 29
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
Matthew R. Weir, Peter A. McCullough, John B. Buse, et al.
American Journal of Nephrology (2020) Vol. 51, Iss. 4, pp. 276-288
Open Access | Times Cited: 27
Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
Wei‐Ting Chang, Sheng‐Nan Wu
Biomedicines (2021) Vol. 9, Iss. 5, pp. 549-549
Open Access | Times Cited: 23
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Hojs, Sebastjan Bevc, Robert Ekart, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 561-561
Open Access | Times Cited: 21
Effects of sodium‐glucose cotransporter‐2 inhibitors and aldosterone antagonists, in addition to renin‐angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta‐analysis
Shuo Yang, Lu Zhao, Yaochuan Mi, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 11, pp. 2159-2168
Closed Access | Times Cited: 16
Finerenone — Halting Relative Hyperaldosteronism in Chronic Kidney Disease
Julie R. Ingelfinger, Clifford J. Rosen
New England Journal of Medicine (2020) Vol. 383, Iss. 23, pp. 2285-2286
Closed Access | Times Cited: 22
Heart failure population health considerations
Jennifer Potash, Rachelle Laliberte, Paul Silverman, et al.
The American Journal of Managed Care (2021) Vol. 27, Iss. Suppl 9, pp. S191-S195
Open Access | Times Cited: 20
T-Cell Mineralocorticoid Receptor Deficiency Attenuates Pathologic Ventricular Remodelling After Myocardial Infarction
Yongli Wang, Xiaoxin Ma, Ruogu Li, et al.
Canadian Journal of Cardiology (2023) Vol. 39, Iss. 5, pp. 593-604
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top